Ovarian cancer is sex hormone-dependent.Gonadotropin releasing hormone (GnRH) analogues inhibit ovarian cancer not only through the hypothalamus-pituitary-gonadal axis, but also through directly inhibiting the proliferation and inducing the apoptosis via GnRH receptors on the ovarian carcinoma cells.In addition, GnRH analogues target GnRH receptors on the cancer cells and can serve as a carrier for cytotoxic agents, improving the efficiency of cytotoxic agents and lowering the side effect.In a word, treatment with GnRH analogues may be a valuable alternative for advanced and recurrent ovarian cancer.